Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug

Kyle LaHucik

Senior Reporter

Intercept Pharmaceuticals is meeting with the FDA later this month in the biotech’s bid to resubmit its drug, obeticholic acid or OCA, for liver scarring …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

As bluebird projects more commercial demand, the biotech continues to seek cash

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Two years af­ter CRL, In­ter­cept will meet with FDA lat­er this month to dis­cuss new analy­sis of NASH drug

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

As bluebird projects more commercial demand, the biotech continues to seek cash

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?